BioNTech lifts 2025 revenue guidance on BMS partnership payment ReutersNovember 3, 2025 at 5:16 PM 0 1 / 2Research laboratory of BioNTech in MainzThe logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023.
- - BioNTech lifts 2025 revenue guidance on BMS partnership payment
ReutersNovember 3, 2025 at 5:16 PM
0
1 / 2Research laboratory of BioNTech in MainzThe logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay
FRANKFURT (Reuters) -Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge Merck's best-selling Keytruda.
BioNTech, Pfizer's partner on COVID-19 vaccines, said it was projecting full-year revenue of 2.6 billion euros ($3.03 billion) to 2.8 billion euros, up from a previous guidance range of 1.7 billion to 2.2 billion euros.
Earlier this year, Bristol agreed to pay up to $11.1 billion in the partnership deal over time, depending on achievements.
BioNTech said on Monday that the partners extended their clinical trial programme for the cancer drug in question, pumitamig, during the third quarter and would add more trials by next year.
The German biotech firm said third-quarter revenue gained 22% to 1.52 billion euros.
BioNTech is pivoting its focus to cancer drugs, which are expected to drive future growth of the company, as revenue from its COVID-19 vaccine steadily decline from their pandemic era highs.
($1 = 0.8575 euros)
(Reporting by Ludwig Burger in Frankfurt and Bhanvi Satija in London, Editing by Miranda Murray)
Source: "AOL Money"
Source: Astro Blog
Full Article on Source: Astro Blog
#LALifestyle #USCelebrities